---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-007655"
form_type: "8-K"
ticker: "ANIK"
cik: "0000898437"
company_name: "Anika Therapeutics, Inc."
filed_at: "2026-01-08T23:59:59+00:00"
generated_at: "2026-05-16T11:17:54.333820+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Anika Therapeutics appoints Steve Griffin CEO effective Feb 1, 2026; Cheryl Blanchard becomes Executive Chair

## Summary
- Steve Griffin, current CFO & COO, promoted to President and CEO effective Feb 1, 2026.
- Cheryl Blanchard transitions from CEO to Executive Chair for 12 months, then Special Advisor.
- Reaffirmed FY2025 guidance: Commercial Channel $47-49.5M (+12-18% YoY), OEM $62-65M (-16-20% YoY).
- Director Susan Vogt resigns effective Feb 1, 2026; no disagreements with the Company.
- Griffin receives $690k base salary, 75% target bonus, and $2.45M equity grant vesting over three years.

## SEC filing metadata
- accession: 0001193125-26-007655
- form_type: 8-K
- ticker: ANIK
- cik: 0000898437
- company_name: Anika Therapeutics, Inc.
- filed_at: 2026-01-08T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/898437/000119312526007655/0001193125-26-007655-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/898437/000119312526007655/d136217d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-007655
- JSON: https://secwatch.observer/filing/0001193125-26-007655.json
- Plain text: https://secwatch.observer/filing/0001193125-26-007655.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.